Eyonis to present clinical evidence for AI-powered lung cancer screening at CHEST 2026
Eyonis, a Median Technologies company, will present study results on the performance of eyonis LCS at the CHEST 2026 conference. The announcements appeared on October 15.
Who is affected and how
- doctor
- Pulmonologists and radiologists can judge the device's screening value from the data to be presented.
Sources
- eyonis Inc., a Median Technologies Company, to Present Study Results Supporting eyonis® LCS Performance Claims at CHEST 2026 - BioSpacebiospace.com · Oct 15, 2026 · magyar
- Eyonis to Present Clinical Evidence for AI-Powered Lung Cancer Screening at CHEST 2026globenewswire · Oct 15, 2026
- Eyonis to Present Clinical Evidence for AI-Powered Lungglobenewswire.com · Oct 15, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.